Europe
Keith Martin to retire as CEO, continue as Non-Executive Director
Start of pivotal US prostate cancer study and treatment of first patients with NanoTherm therapy following U.S. FDA IDE approval in February and IRB approvals in April of this year
Oxurion NV announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview at the Ophthalmology Innovation Summit (OIS@AAO 2018) at 3:55 p.m. CDT on Thursday, Oct. 25, 2018 in Chicago, Illinois.
Polyphor presented new efficacy data on its immuno-oncology candidate, balixafortide, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
Santhera Pharmaceuticals announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF).
Cash position of EUR 44.2 million as of September 30, 2018
NOXXON Pharma N.V. announced today that the company will attend the BIO-Europe Conference and the Salon Actionaria in November 2018.
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that that it has had a successful meeting with the US Food and Drug Administration (FDA) regarding the continued development of PXL01.
Next-Generation Thoracic Endovascular Repair (TEVAR) Device Expands Applicability to Broader Range of Patients
Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).
PRESS RELEASES